SamuelSanchez RiveraMD

Clinical Trials

• Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients Start of enrollment: 2003 Sep 01

  Terminated

  Phase 2

• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01

  Completed

  Phase 3

• Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris Start of enrollment: 2015 Nov 01

  Completed

  Phase 3

• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28

  Completed

  Phase 3

• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine Start of enrollment: 2018 Mar 14

  Recruiting

  Phase 3

• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Start of enrollment: 2018 Jun 26

  Completed

  Phase 3

• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Start of enrollment: 2018 Sep 03

  Terminated

  Phase 3

• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27

  Terminated

  Phase 3

• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Aug 09

  Enrolling by invitation

  Phase 3

• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2018 Nov 09

  Completed

  Phase 4

• A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Dec 27

  Completed

  Phase 2

• A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2019 May 13

  Completed

  Phase 3

• Join now to see all